person · Reporting owner

Desai Antal Rohit

Disclosed activity across 3 companies

Tapewire entity: 39711
SEC CIK: 0001881616

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
PROCEPT BioRobotics CorpPRCT · Entity 4831	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PROCEPT BioRobotics Corp

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	38,467	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 38,467 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08	Direct	5,853	Reported balance After 2026-06-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Apollo Endosurgery, Inc.

Report date April 04, 2023 · Filed April 05, 2023

Jointly reported with CPMG Inc

Section 16 reporting ended · disclosed 2023-04-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Curlew Fund, LP	Reported balance After 2023-04-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-04-04 · Disposition to issuer · Disposed 675,181 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Killdeer Fund, LP	Reported balance After 2023-04-04 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-04-04 · Disposition to issuer · Disposed 1,310,701 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Roadrunner Fund, LP	Reported balance After 2023-04-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2023-04-04 · Disposition to issuer · Disposed 3,687,781 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Crested Crane, LP	Reported balance After 2023-04-04 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2023-04-04 · Disposition to issuer · Disposed 45,594 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Kestrel Fund, LP	Reported balance After 2023-04-04 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2023-04-04 · Disposition to issuer · Disposed 63,671 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Mallard Fund, LP	Reported balance After 2023-04-04 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2023-04-04 · Disposition to issuer · Disposed 400,675 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4.

F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions.

REATA PHARMACEUTICALS INC

Report date September 26, 2023 · Filed September 28, 2023

Jointly reported with CPMG Inc

Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Class A common stockSEC Table I · non-derivative	IndirectBy The 2:22 DNA Trust	Reported balance After 2023-09-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-09-26 · Disposition to issuer · Disposed 31,467 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F1: Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy CPMG, Inc.	Reported balance After 2023-09-26 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-09-26 · Disposition to issuer · Disposed 113 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Nighthawk Partners, LP	Reported balance After 2023-09-26 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2023-09-26 · Disposition to issuer · Disposed 116,512 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Willet Fund, LP	Reported balance After 2023-09-26 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2023-09-26 · Disposition to issuer · Disposed 282,246 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Killdeer Fund, LP	Reported balance After 2023-09-26 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2023-09-26 · Disposition to issuer · Disposed 137,962 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Elepaio Partners, LP	Reported balance After 2023-09-26 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2023-09-26 · Disposition to issuer · Disposed 5,464 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Barred Owl Partners, LP	Reported balance After 2023-09-26 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2023-09-26 · Disposition to issuer · Disposed 44,200 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Managed Account for Trustees of the University of Pennsylvania	Reported balance After 2023-09-26 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2023-09-26 · Disposition to issuer · Disposed 34,897 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Gallopavo, LP	Reported balance After 2023-09-26 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2023-09-26 · Disposition to issuer · Disposed 442,560 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Roadrunner Fund, LP	Reported balance After 2023-09-26 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2023-09-26 · Disposition to issuer · Disposed 748,253 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Yellow Warbler, LP	Reported balance After 2023-09-26 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2023-09-26 · Disposition to issuer · Disposed 431,155 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Mallard Fund, LP	Reported balance After 2023-09-26 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2023-09-26 · Disposition to issuer · Disposed 109,415 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Crested Crane, LP	Reported balance After 2023-09-26 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2023-09-26 · Disposition to issuer · Disposed 37,909 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Sandpiper Fund, LP	Reported balance After 2023-09-26 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2023-09-26 · Disposition to issuer · Disposed 334,740 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Kestrel Fund, LP(	Reported balance After 2023-09-26 transaction · row 15 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 15 · 2023-09-26 · Disposition to issuer · Disposed 160,265 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy CD Fund, LP	Reported balance After 2023-09-26 transaction · row 16 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 16 · 2023-09-26 · Disposition to issuer · Disposed 11,076 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class A common stockSEC Table I · non-derivative	IndirectBy Redbird Life Sciences Partners, LP	Reported balance After 2023-09-26 transaction · row 17 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 17 · 2023-09-26 · Disposition to issuer · Disposed 134 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy CPMG, Inc.	Reported balance After 2023-09-26 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2023-09-26 · Disposition to issuer · Disposed 1,251 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy Mallard Fund, LP	Reported balance After 2023-09-26 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2023-09-26 · Disposition to issuer · Disposed 150,186 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy Kestrel Fund, LP	Reported balance After 2023-09-26 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2023-09-26 · Disposition to issuer · Disposed 307,776 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy CD Fund, LP	Reported balance After 2023-09-26 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2023-09-26 · Disposition to issuer · Disposed 123,279 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy Redbird Life Sciences Partners, LP	Reported balance After 2023-09-26 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2023-09-26 · Disposition to issuer · Disposed 1,490 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy Willet Fund, LP	Reported balance After 2023-09-26 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2023-09-26 · Disposition to issuer · Disposed 114,946 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Class B common stockSEC Table II · derivative / convertible security	IndirectBy Yellow Warbler, LP	Reported balance After 2023-09-26 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2023-09-26 · Disposition to issuer · Disposed 993,929 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust.

F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4.

F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes.

F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 12, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	9,402	$79.78	$750,096.26	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 9 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 226,142 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.33 to $80.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 12, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	2,318	$78.89	$182,876.06	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 8 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 235,544 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $79.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 12, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	4,458	$78.00	$347,703.05	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 7 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 237,862 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 11, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	4,182	$78.67	$329,005.47	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 6 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 242,320 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.48 to $79.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 11, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	20,732	$78.12	$1,619,598.35	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 5 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 246,502 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.48 to $78.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 11, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	4,880	$77.09	$376,197.25	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 4 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 267,234 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.46 to $77.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 11, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	8,904	$75.90	$675,846.54	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 3 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 272,114 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.435 to $76.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 10, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	17,810	$76.60	$1,364,217.50	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 2 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 281,018 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.24 to $76.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 10, 2024 Filed Sep 13, 2024 00:03 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	18,690	$75.78	$1,416,352.50	Disclosure SEC source: 0001628280-24-040284 · wk-form4_1726185775.xml · nonDerivative · entry 1 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 298,828 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 05, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	900	$76.96	$69,262.02	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 13 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 317,518 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.79 to $77.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 05, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	12,405	$76.33	$946,822.79	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 12 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 318,418 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.78 to $76.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 04, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	400	$76.37	$30,547.00	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 11 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 330,823 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.24 to $76.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 04, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	23,164	$75.69	$1,753,250.73	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 10 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 331,223 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.23 to $76.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 04, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	12,648	$74.90	$947,323.82	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 9 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By The 2:22 DNA Trust Disclosed balance after: 354,387 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.23 to $75.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 04, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	200	$76.41	$15,281.00	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 8 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,543 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.33 to $76.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 04, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	10,998	$75.70	$832,515.61	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 7 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,743 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.25 to $76.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 04, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	6,222	$74.91	$466,079.44	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 6 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,741 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.25 to $75.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 03, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	100	$78.91	$7,891.00	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 5 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,963 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. Read SEC document
September 03, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	1,000	$78.00	$77,999.00	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 4 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.90 to $78.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 03, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	3,629	$77.23	$280,257.87	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 3 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 03, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	19,725	$76.32	$1,505,368.61	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 2 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.85 to $76.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
September 03, 2024 Filed Sep 5, 2024 23:13 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	SaleCommon Stock	10,766	$75.17	$809,294.22	Disclosure SEC source: 0001628280-24-039573 · wk-form4_1725578026.xml · nonDerivative · entry 1 Desai Antal Rohit · CIK 0001881616 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,417 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.85 to $75.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:33 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantStock Option (Right to Buy) · Derivative	2,526	$0.00 Strike: $67.29	$0.00	Disclosure SEC source: 0001628280-24-027068 · wk-form4_1717706010.xml · derivative · entry 2 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,526 Underlying: Common Stock · 2,526 shares Expires 2034-06-03 F2 · derivative.exercise_date: The Stock Option was granted on June 4, 2024 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:33 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock	1,376	$0.00	$0.00	Disclosure SEC source: 0001628280-24-027068 · wk-form4_1717706010.xml · nonDerivative · entry 1 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,183 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
May 20, 2024 Filed May 23, 2024 01:31 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	OtherCommon Stock	164,063	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001579 · form4.xml · nonDerivative · entry 2 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Mallard Fund, L.P. Disclosed balance after: 180,527 F3 · kind: On May 20, 2024, Mallard Fund, L.P. distributed shares on a pro rata basis, for no consideration, including 37 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F3 · balance_after: On May 20, 2024, Mallard Fund, L.P. distributed shares on a pro rata basis, for no consideration, including 37 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F1 · ownership.nature: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Read SEC document
May 20, 2024 Filed May 23, 2024 01:31 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	OtherCommon Stock	1,949,104	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001579 · form4.xml · nonDerivative · entry 1 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By White Tailed Ptarmigan, LP Disclosed balance after: 711,547 F2 · kind: On May 20, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 163,030 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F2 · balance_after: On May 20, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 163,030 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F1 · ownership.nature: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Read SEC document
May 03, 2024 Filed May 8, 2024 01:45 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	OtherCommon Stock	1,785,127	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001299 · form4.xml · nonDerivative · entry 1 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By White Tailed Ptarmigan, LP Disclosed balance after: 2,823,681 F2 · kind: On May 3, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 421,061 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F2 · balance_after: On May 3, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 421,061 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F1 · ownership.nature: Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Kent McGaughy, Jr., CPMG, Inc. and White Tailed Ptarmigan, LP jointly report their beneficial ownership of these shares on a separate Form 4. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	993,929	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 24 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Yellow Warbler, LP Disclosed balance after: 0 Underlying: Class A common stock · 993,929 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	114,946	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 23 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Willet Fund, LP Disclosed balance after: 0 Underlying: Class A common stock · 114,946 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	1,490	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 22 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Redbird Life Sciences Partners, LP Disclosed balance after: 0 Underlying: Class A common stock · 1,490 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	123,279	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 21 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By CD Fund, LP Disclosed balance after: 0 Underlying: Class A common stock · 123,279 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	307,776	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 20 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kestrel Fund, LP Disclosed balance after: 0 Underlying: Class A common stock · 307,776 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	150,186	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 19 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Mallard Fund, LP Disclosed balance after: 0 Underlying: Class A common stock · 150,186 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass B common stock · Derivative	1,251	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · derivative · entry 18 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By CPMG, Inc. Disclosed balance after: 0 Underlying: Class A common stock · 1,251 shares Expires not disclosed F5 · derivative.exercise_price: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F5 · derivative.exercise_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F5 · derivative.expiration_date: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	134	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 17 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Redbird Life Sciences Partners, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	11,076	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 16 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By CD Fund, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	160,265	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 15 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kestrel Fund, LP( Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	334,740	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 14 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sandpiper Fund, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	37,909	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 13 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Crested Crane, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	109,415	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 12 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Mallard Fund, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	431,155	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 11 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Yellow Warbler, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	748,253	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 10 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	442,560	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 9 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Gallopavo, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	34,897	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 8 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed Account for Trustees of the University of Pennsylvania Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	44,200	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 7 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Barred Owl Partners, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	5,464	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 6 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Elepaio Partners, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	137,962	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 5 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	282,246	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 4 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Willet Fund, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	116,512	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 3 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nighthawk Partners, LP Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:32 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	Disposition to issuerClass A common stock	113	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-23-001027 · form4.xml · nonDerivative · entry 2 Desai Antal Rohit · CIK 0001881616 · Director · 10% owner CPMG Inc · CIK 0001372218 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By CPMG, Inc. Disclosed balance after: 0 F4 · price: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2 · ownership.direct: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.direct: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. F2 · ownership.nature: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3 · ownership.nature: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.